ATE232739T1 - Protein c zur behandlung von sichelzellanämie und thalassämie - Google Patents

Protein c zur behandlung von sichelzellanämie und thalassämie

Info

Publication number
ATE232739T1
ATE232739T1 AT99960334T AT99960334T ATE232739T1 AT E232739 T1 ATE232739 T1 AT E232739T1 AT 99960334 T AT99960334 T AT 99960334T AT 99960334 T AT99960334 T AT 99960334T AT E232739 T1 ATE232739 T1 AT E232739T1
Authority
AT
Austria
Prior art keywords
thalassemia
protein
treatment
sickle cell
cell anemia
Prior art date
Application number
AT99960334T
Other languages
English (en)
Inventor
Suzanne Lee Um
Sau-Chi Betty Yan
Barbara Gail Utterback
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE232739T1 publication Critical patent/ATE232739T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
AT99960334T 1998-11-23 1999-11-16 Protein c zur behandlung von sichelzellanämie und thalassämie ATE232739T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10947498P 1998-11-23 1998-11-23
PCT/US1999/026958 WO2000030676A1 (en) 1998-11-23 1999-11-16 Method of treating sickle cell disease and thalassemia

Publications (1)

Publication Number Publication Date
ATE232739T1 true ATE232739T1 (de) 2003-03-15

Family

ID=22327841

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99960334T ATE232739T1 (de) 1998-11-23 1999-11-16 Protein c zur behandlung von sichelzellanämie und thalassämie

Country Status (14)

Country Link
US (1) US6372213B2 (de)
EP (1) EP1133314B1 (de)
JP (1) JP2002530352A (de)
CN (1) CN1326357A (de)
AT (1) ATE232739T1 (de)
AU (1) AU1723200A (de)
BR (1) BR9915572A (de)
CA (1) CA2351591A1 (de)
DE (1) DE69905489T2 (de)
DK (1) DK1133314T3 (de)
ES (1) ES2192874T3 (de)
IL (1) IL142247A0 (de)
WO (1) WO2000030676A1 (de)
ZA (1) ZA200102727B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001290553A1 (en) * 2000-09-18 2002-04-02 Eli Lilly And Company Method for using activated protein c for the treatment of coagulation-associated disorders
US20060246161A1 (en) * 2003-02-21 2006-11-02 Hongtao Xing Method of making medicament for treating anemia
EP2815749A1 (de) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Feste Form von 4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion mit spezifischem Röntgenbeugungsspektrum
WO2018013693A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
WO2018013689A1 (en) 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
CN106399478A (zh) 2016-08-31 2017-02-15 桂林优利特医疗电子有限公司 一种荧光探针PCR 法快速检测α/β‑地中海贫血的试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
GB8819607D0 (en) 1988-08-17 1988-09-21 Wellcome Found Novel combination
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
AT402262B (de) 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
EA004881B1 (ru) * 1997-04-28 2004-08-26 Эли Лилли Энд Компани Лиофилизированные композиции на основе рекомбинантного человеческого активированного протеина с и их применение
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
AU1723200A (en) 2000-06-13
CA2351591A1 (en) 2000-06-02
ES2192874T3 (es) 2003-10-16
US20020012662A1 (en) 2002-01-31
JP2002530352A (ja) 2002-09-17
US6372213B2 (en) 2002-04-16
BR9915572A (pt) 2001-08-14
DE69905489T2 (de) 2003-09-11
DK1133314T3 (da) 2003-04-14
CN1326357A (zh) 2001-12-12
WO2000030676A1 (en) 2000-06-02
ZA200102727B (en) 2002-09-25
IL142247A0 (en) 2002-03-10
EP1133314A1 (de) 2001-09-19
DE69905489D1 (de) 2003-03-27
EP1133314B1 (de) 2003-02-19

Similar Documents

Publication Publication Date Title
DE69200675D1 (de) Verwendung von Droloxifen bei der Behandlung von Knochenerkrankungen.
IS4226A (is) Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum
DE69508192T2 (de) Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
FR2856294B1 (fr) Utilisation cosmetique d'une composition comprenant au moins une oxazoline, a titre de principe actif, comme amincissant et/ou pour prevenir et/ou traiter la cellulite
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
ATE232739T1 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE235915T1 (de) Behandlung von hämorrhagischem virusfieber mit protein c
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
DE68913995D1 (de) Zusammensetzung zur behandlung progressiver myopie.
ATE258550T1 (de) Oxirancarbonsäuren für die behandlung von diabetes
WO1998023574A8 (en) Asiatic acid derivatives and medicines for treating wounds, which contains the same
ATE311901T1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
NO20012169D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
DE602005020618D1 (de) Verwendung von neboglamine zur behandlung von schizophrenie
DE68916814D1 (de) Mittel zur behandlung von pediculosis capitis.
ATE223211T1 (de) Verwendung von kalzium dobesilat zur herstellung eines arzneimittels zur behandlung von embryonaler zurückgebliebenheit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1133314

Country of ref document: EP

REN Ceased due to non-payment of the annual fee